Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294005 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL1294003 | 0.89 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL17396071 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL17396070 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL24733173 | 0.87 | ALDH1A1 (0.43) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL15367045 | 0.85 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL12066763 | 0.85 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL15773460 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL28152177 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL1914149 | 0.83 | HCRTR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072523-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072523-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011079327-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079327-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072523-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | C1QBP, IRF3, IFNAR1 | ALDH1A1 1562/4885TSHR 1754/4885L3MBTL1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.